Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat with Biotech Equity Research Managing Director Silvan Tuerkcan on May 8 at 1:30 p.m. ET. The discussion will focus on the company's clinical-stage programs and upcoming milestones.
The event will be accessible via webcast, with a replay available for 90 days on Genelux's IR page. The company will also conduct one-on-one meetings with institutional investors during the conference.
Genelux Corporation (NASDAQ: GNLX), un'azienda immuno-oncologica in fase clinica avanzata, ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference a New York, il 7 e 8 maggio 2025. Il CEO e Presidente Thomas Zindrick e il CFO Matt Pulisic parteciperanno a una conversazione informale con Silvan Tuerkcan, Managing Director di Biotech Equity Research, l'8 maggio alle 13:30 ET. Il dibattito verter脿 sui programmi clinici dell'azienda e sulle prossime tappe fondamentali.
L'evento sar脿 accessibile tramite webcast, con una replica disponibile per 90 giorni sulla pagina IR di Genelux. Durante la conferenza, l'azienda terr脿 anche incontri individuali con investitori istituzionali.
Genelux Corporation (NASDAQ: GNLX), una empresa de inmunooncolog铆a en etapa cl铆nica avanzada, ha anunciado su participaci贸n en la pr贸xima Citizens Life Sciences Conference en Nueva York, los d铆as 7 y 8 de mayo de 2025. El CEO y presidente Thomas Zindrick y el CFO Matt Pulisic participar谩n en una charla informal con Silvan Tuerkcan, Director General de Biotech Equity Research, el 8 de mayo a la 1:30 p.m. ET. La discusi贸n se centrar谩 en los programas en etapa cl铆nica de la empresa y los pr贸ximos hitos.
El evento estar谩 disponible v铆a webcast, con una repetici贸n accesible durante 90 d铆as en la p谩gina de relaciones con inversores de Genelux. La empresa tambi茅n llevar谩 a cabo reuniones individuales con inversores institucionales durante la conferencia.
Genelux Corporation (NASDAQ: GNLX)電� 頉勱赴 鞛勳儊 雼硠 氅挫棴膦呾枒頃� 須岇偓搿滌劀, 2025雲� 5鞗� 7鞚茧秬韯� 8鞚缄箤歆� 雺挫殨鞐愳劀 鞐措Μ電� Citizens Life Sciences Conference鞐� 彀胳棳頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. CEO 瓴� 須岇灔鞚� Thomas Zindrick鞕� CFO Matt Pulisic電� 5鞗� 8鞚� 鞓ろ泟 1鞁� 30攵�(霃欕秬鞁滉皠)鞐� Biotech Equity Research鞚� 鞝勲鞚挫偓 Silvan Tuerkcan瓿� 頃粯 韺岇澊鞏挫偓鞚措摐 毂勴寘鞚� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 鞚措矆 雽�頇旊姅 須岇偓鞚� 鞛勳儊 雼硠 頂勲攴鸽灗瓿� 雼り皜鞓る姅 欤检殧 鞚检爼鞐� 齑堨爯鞚� 毵烄稖 瓴冹瀰雼堧嫟.
鞚� 頄夓偓電� 鞗轨簮鞀ろ姼搿� 鞁滌箔 臧�電ロ晿氅�, 雼れ嫓氤搓赴 鞓侅儊鞚� Genelux鞚� IR 韼橃澊歆�鞐愳劀 90鞚缄皠 鞝滉车霅╇媹雼�. 霕愴暅, 須岇偓電� 旎嵓霟办姢 旮瓣皠 霃欖晥 旮瓣磤 韴瀽鞛愲摛瓿� 鞚茧寑鞚� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
Genelux Corporation (NASDAQ : GNLX), une soci茅t茅 d'immuno-oncologie en phase clinique avanc茅e, a annonc茅 sa participation 脿 la prochaine Citizens Life Sciences Conference 脿 New York, les 7 et 8 mai 2025. Le PDG et pr茅sident Thomas Zindrick ainsi que le directeur financier Matt Pulisic participeront 脿 une discussion informelle avec Silvan Tuerkcan, directeur g茅n茅ral de Biotech Equity Research, le 8 mai 脿 13h30 ET. La discussion portera sur les programmes cliniques de la soci茅t茅 et les prochaines 茅tapes importantes.
L'茅v茅nement sera accessible via webcast, avec une rediffusion disponible pendant 90 jours sur la page IR de Genelux. La soci茅t茅 organisera 茅galement des r茅unions individuelles avec des investisseurs institutionnels lors de la conf茅rence.
Genelux Corporation (NASDAQ: GNLX), ein Immunonkologie-Unternehmen in fortgeschrittener klinischer Phase, hat seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference in New York am 7. und 8. Mai 2025 bekanntgegeben. CEO und Vorsitzender Thomas Zindrick sowie CFO Matt Pulisic werden am 8. Mai um 13:30 Uhr ET an einem Fireside-Chat mit Silvan Tuerkcan, Managing Director von Biotech Equity Research, teilnehmen. Die Diskussion wird sich auf die klinischen Programme des Unternehmens und bevorstehende Meilensteine konzentrieren.
Die Veranstaltung wird per Webcast zug盲nglich sein, mit einer Wiederholung, die f眉r 90 Tage auf der IR-Seite von Genelux verf眉gbar ist. Das Unternehmen wird w盲hrend der Konferenz auch Einzelgespr盲che mit institutionellen Investoren f眉hren.
- None.
- None.
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board, and , CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York.
The conversation with聽Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at聽1:30 p.m. ET on Thursday, May 8, 2025. A webcast link for the event will be available at . An archived replay will be available for approximately 90 days following the event on the company鈥檚 IR page.
The Company will also attend one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference or contact [email protected].
About Genelux Corporation
Genelux聽is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two聽U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a聽China-based, multi-center, open label Ph1b evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet in recurrent small-cell lung cancer.聽 The core of聽Genelux's聽discovery and development efforts revolves around its鈥� proprietary CHOICE鈩� platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit and follow us on Twitter and on .
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
[email protected]
Source: Genelux Corporation
FAQ
When is Genelux (GNLX) presenting at the Citizens Life Sciences Conference 2025?
Who will represent Genelux (GNLX) at the Citizens Life Sciences Conference?
What topics will Genelux (GNLX) discuss at the Citizens Life Sciences Conference?
How can investors access Genelux's (GNLX) presentation at the Citizens Life Sciences Conference?
